PMID- 10509381
OWN - NLM
STAT- MEDLINE
DCOM- 19991202
LR  - 20190910
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 23
IP  - 5
DP  - 1999 Jul
TI  - Lysosphingomyelin prevents behavioral aberrations and hippocampal neuron loss 
      induced by the metabotropic glutamate receptor agonist quisqualate.
PG  - 877-92
AB  - 1. Excessive excitation of brain neurons by the excitatory neurotransmitter, 
      glutamate, induces a cascade of events leading to increased intracellular Ca++, 
      neuronal degeneration and death. 2. Recent in vitro research has demonstrated 
      that a natural cationic amphiphile in the brain, lysosphingomyelin, may be able 
      to prevent neuronal degeneration by repressing phosphosinositidase-C 
      overactivation induced by excessive excitation of the metabotropic glutamate 
      receptor. 3. This research tested the latter finding in vivo in a rat model of 
      glutamate excitotoxicity. Intracerebroventricular (i.c.v.) administration of the 
      Group 1 metabotropic glutamate receptor (mGluR) agonist, quisqualate, produced 
      seizures, akinesia, destruction of hippocampal pyramidal cell dendritic 
      microtubule-associated protein-2, and major loss of hippocampal CA sector 
      neurons. 4. Prophylactic i.c.v. infusion of lysosphingomyelin powerfully 
      attenuates these quisqualate-induced behaviors and prevents neuronal 
      degeneration. 5. Lysosphingomyelin may be of clinical use in allaying progressive 
      Group 1 mGluR-induced hippocampal cognitive and motor disorders including 
      Alzheimer's disease, brain seizure, and stroke.
FAU - Hodgson, D M
AU  - Hodgson DM
AD  - Dept. of Neurobiology, School of Medicine, University of California, Los Angeles, 
      USA.
FAU - Taylor, A N
AU  - Taylor AN
FAU - Zhang, Z
AU  - Zhang Z
FAU - Rosenberg, A
AU  - Rosenberg A
LA  - eng
GR  - AA09660/AA/NIAAA NIH HHS/United States
GR  - AA09850/AA/NIAAA NIH HHS/United States
GR  - DA11146/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Excitatory Amino Acid Agonists)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Receptors, Metabotropic Glutamate)
RN  - 10216-23-6 (sphingosine phosphorylcholine)
RN  - 107-73-3 (Phosphorylcholine)
RN  - 8OC22C1B99 (Quisqualic Acid)
RN  - NGZ37HRE42 (Sphingosine)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Dyskinesia, Drug-Induced/psychology
MH  - Excitatory Amino Acid Agonists/administration & dosage/*toxicity
MH  - Hippocampus/drug effects/*pathology
MH  - Immunohistochemistry
MH  - Injections, Intraventricular
MH  - Lateral Ventricles
MH  - Male
MH  - Microtubule-Associated Proteins/metabolism
MH  - Neurons/drug effects/*pathology
MH  - Phosphorylcholine/*analogs & derivatives/pharmacology
MH  - Quisqualic Acid/administration & dosage/*antagonists & inhibitors/*toxicity
MH  - Rats
MH  - Rats, Inbred F344
MH  - Receptors, Metabotropic Glutamate/*antagonists & inhibitors
MH  - Seizures/chemically induced
MH  - Sphingosine/*analogs & derivatives/pharmacology
EDAT- 1999/10/06 00:00
MHDA- 1999/10/06 00:01
CRDT- 1999/10/06 00:00
PHST- 1999/10/06 00:00 [pubmed]
PHST- 1999/10/06 00:01 [medline]
PHST- 1999/10/06 00:00 [entrez]
AID - S0278-5846(99)00047-0 [pii]
AID - 10.1016/s0278-5846(99)00047-0 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 1999 Jul;23(5):877-92. doi: 
      10.1016/s0278-5846(99)00047-0.